Alimera Sciences files $75M IPO
Alimera Sciences is braving a badly roiled public market with plans to push a $75 million IPO. The Atlanta-based biotech is developing ophthalmic drugs. Credit Suisse, Citi, Cowen and Co. and Leerink Swann are underwriting the IPO. Alimera has raised more than $71 million from a group of venture capital groups that include Scale Venture Partners, Domain Associates, Intersouth Partners and Polaris Venture Partners. In addition to developing new therapies, Alimera also markets OTC ophthalmic products. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
